Iqbal Hussain Sells 38,951 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) insider Iqbal Hussain sold 38,951 shares of the business’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $25.15, for a total transaction of $979,617.65. Following the transaction, the insider owned 57,645 shares in the company, valued at approximately $1,449,771.75. This trade represents a 40.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Centessa Pharmaceuticals Stock Up 1.2%

Shares of NASDAQ:CNTA traded up $0.29 during midday trading on Tuesday, reaching $25.48. The company had a trading volume of 1,005,598 shares, compared to its average volume of 1,624,695. The stock has a market capitalization of $3.43 billion, a P/E ratio of -13.92 and a beta of 1.56. The stock’s fifty day moving average price is $25.47 and its 200-day moving average price is $22.53. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.56 and a quick ratio of 10.57. Centessa Pharmaceuticals PLC Sponsored ADR has a one year low of $9.60 and a one year high of $30.58.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.02). Equities research analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Oppenheimer lifted their target price on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. Chardan Capital reissued a “buy” rating and issued a $30.00 price objective on shares of Centessa Pharmaceuticals in a report on Friday, January 2nd. Guggenheim lifted their target price on Centessa Pharmaceuticals from $28.00 to $43.00 and gave the stock a “buy” rating in a report on Tuesday, November 18th. Finally, Wells Fargo & Company increased their price target on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $38.50.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the company. Millennium Management LLC raised its stake in shares of Centessa Pharmaceuticals by 52.9% during the first quarter. Millennium Management LLC now owns 609,188 shares of the company’s stock worth $8,760,000 after buying an additional 210,737 shares during the last quarter. Jane Street Group LLC acquired a new stake in Centessa Pharmaceuticals during the 1st quarter worth $2,176,000. Aberdeen Group plc lifted its stake in shares of Centessa Pharmaceuticals by 31.4% in the 2nd quarter. Aberdeen Group plc now owns 119,389 shares of the company’s stock valued at $1,569,000 after purchasing an additional 28,506 shares during the period. Windmill Hill Asset Management Ltd boosted its position in shares of Centessa Pharmaceuticals by 38.9% in the 2nd quarter. Windmill Hill Asset Management Ltd now owns 163,768 shares of the company’s stock worth $2,152,000 after purchasing an additional 45,855 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd acquired a new stake in shares of Centessa Pharmaceuticals during the second quarter worth $613,000. Institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.